Skip to main content

Table 2 Pharmacokinetic parameters

From: A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

  0.06 mg/kg ALT-836 0.08 mg/kg ALT-836 0.1 mg/kg ALT-836
t1/2 term., hour 18.5 ± 5.9 22.6 ± 3.1 22.6 ± 6.2
Cmax, ng/ml (nM) 1,300 ± 560 (8.6) 1,490 ± 340 (9.9) 1,800 ± 250 (12.0)
Vd, ml/kg 46.1 ± 13.1 47.7 ± 16.0 54.5 ± 6.6
Cl, ml/hr/kg 1.9 ± 1.0 1.5 ± 0.7 1.8 ± 0.4
AUCINF, hr·ng/ml 39,000 ± 24,200 59,900 ± 20,500 59,900 ± 16,600
  1. t1/2 term., terminal half-life; Cmax, maximum serum concentration; Vd, volume of distribution; Cl, total body clearance: AUCINF, area under the drug concentration versus time curve extrapolated to infinity
  2. Values are means ± SD